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Abstract Bariatric surgery is now widely accepted for treat-
ment of morbid obesity. This study compared the effects of
laparoscopic sleeve gastrectomy (LSG) and laparoscopic ad-
justable gastric banding (LAGB) on excess weight loss
(EWL) and type 2 diabetes mellitus (T2DM). PubMed and
Embase were searched for publications concerning LAGB
and LSG from 2000 to 2012, with the last search on August
17, 2012. EWL and T2DM improvement over 6 and
12months were pooled and compared by meta-analysis. Odds
ratios (ORs) and mean differences were calculated with 95 %
confidence intervals (CIs). Eleven studies involving 1,004
patients met the inclusion criteria. Compared with LAGB,
LSG achieved greater EWL. The mean percentage EWL for
LAGB was 33.9 % after 6 months in six studies and 37.8 %
after 12 months in four studies; for LSG, EWL was 50.6 %
after 6 months and 51.8% after 12months in the same studies.
LSG was also superior to LAGB in treating T2DM. In five
studies, T2DM was improved in 42 of 68 (61.8 %) patients
after LAGB and 66 of 80 (82.5 %) after LSG, representing a
pooled OR of 0.34 (95 % CI 0.16–0.73) and pooled mean
differences of −12.55 (95 % CI −15.66 to −9.43) and −4.97
(95 % CI −7.58 to −8.36), respectively. LSG is more effective
than LAGB in morbid obesity, with higher percentage EWL
and greater improvement in T2DM.
Keywords Laparoscopic sleeve gastrectomy . Laparoscopic
adjustable gastric banding .Type 2diabetesmellitus .Morbid
obesity . Bariatric surgery
Abbreviations
LSG Laparoscopic sleeve gastrectomy
LAGB Laparoscopic adjustable gastric banding
T2DM Type 2 diabetes mellitus
EWL Excess weight loss
LRYGB Laparoscopic Roux-en-Y gastric bypass
BPD/DS Biliopancreatic diversion with duodenal switch
PYY Peptide tyrosine–tyrosine
GLP-1 Glucagon-like peptide 1
Introduction
Morbid obesity is increasing worldwide. Its prevalence is
higher in developed countries such as the USA and Western
European nations than in developing countries [1], but it is also
increasing in Asia and other regions due to lack of exercise,
lifestyle changes, and greater stress. In China, morbid obesity is
strongly associated with type 2 diabetes mellitus (T2DM),
which has become a serious problem in modern Chinese soci-
ety [2]. Over 90 million patients suffer from diabetes in China,
90 % of whom have T2DM [4]. Morbid obesity is also linked
with hypertension, obstructive sleep apnea, and other
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conditions that cause distress to patients and reduce their quality
of life. Obesity also increases the risk of heart attack and death.
People who are slightly overweight may find medical
treatments to lose weight effective. However, pharmacologic
and behavioral treatments for morbid obesity usually do not
work in the long term, with patients regaining the weight they
lost. Similarly, common medical treatments cannot always
resolve diabetes mellitus and hypertension. According to a
National Institutes of Health consensus statement in 1991,
bariatric surgery is the only way to guarantee substantial
weight loss and maintain weight at a reasonable level [3].
Bariatric surgery can also improve or even resolve obesity-
related comorbidities, especially T2DM.
Three types of bariatric surgery are performed widely and
proven effective: laparoscopic Roux-en-Y gastric bypass, lapa-
roscopic sleeve gastrectomy (LSG) and laparoscopic adjustable
gastric banding (LAGB). LAGB is a simple and safe procedure
that restricts food intake using an adjustable band, which is
placed around the upper stomach to create a gastric pouch that
is distended duringmeals and connected to a reservoir under the
skin to change its diameter [4]. LSG is a comparatively new
technique that is safe and effective especially in super-obese
patients. It involves resection of two thirds of the stomach,
including the fundus, while the remaining part from the gastro-
esophageal junction to the pylorus along the great curvature is
used to form a “sleeve”. This procedure decreases the volume
of the stomach to about 100 ml, which is easier to fill and thus
leads to less food intake [5]. Although comparatively new, LSG
is reported to be superior to LAGB in its effects on morbid
obesity. In this meta-analysis, we aimed to compare the out-
comes of LAGB and LSG in terms of excess weight loss
(EWL) and improvement of T2DM.
Materials and Methods
Search Strategies
Two databases (PubMed and Embase) were searched for all
relevant literature, including references in articles, published
between 2000 and 2012. The medical subject headings and
keywords searched for individually and in combination were
as follows: “laparoscopic adjustable gastric banding”, “laparo-
scopic sleeve gastrectomy”, “type 2 diabetes mellitus”, “bar-
iatric surgery”, and “morbid obesity”. The last search was
conducted on August 17, 2012.
Inclusion and Exclusion Criteria
The inclusion criteria were as follows: (1) studies including
randomized controlled trials and non-randomized studies
that compared LAGB with LSG, (2) studies that provided
information on at least one of the outcome measures, and (3)
studies published in English. When a study reporting the
same patient cohort was included in several publications,
only the most recent or complete study was selected. The
exclusion criteria were as follows: (1) case reports, (2)
articles that were not full text or non-comparative studies,
and (3) open operations, not by laparoscopic surgery.
Data Extraction
All included studies were assessed for the quality of their
methodology and relevance to the objective of our meta-
analysis. Conduct and reporting were in accordance with the
QUOROM statement. Data on EWL and improvement of
Fig. 1 Forest plot of
comparison: (1) LAGB vs LSG
in terms of short-term results,
outcome: (1.1) resolution of
diabetes. Odds ratios are shown
with 95 % CIs
Fig. 2 Forest plot of comparison: (1) LAGB vs LSG in terms of short-term results, outcome: (1.2) EWL% (6 months). Mean differences are shown
with 95 % CIs
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T2DM from each trial were extracted and compared inde-
pendently by the two investigators.
Statistical Analysis
Statistical analysis was conducted using Review Manager
software version 5.0.0 (Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, Denmark). Pooled
odds ratios (ORs) and pooled mean differences with 95 %
confidence intervals (CIs) were used to assess the outcomes
of the studies; statistical heterogeneity was tested by the chi-
square test. According to forest plots, heterogeneity was
limited; thus, we used the Mantel–Haenszel fixed effect
model. The significance of the pooled ORs was determined
by Z-test, and statistical significance was set at p<0.05.
Results
Study Characteristics
There were 11 studies in this meta-analysis [1, 3, 5–13]
(Tables 1 and 2). All were published in or after 2005 and most
were published during the last 3 years. The meta-analysis
included 1,004 patients from these studies, of whom 616
underwent LAGB and 388 underwent LSG. Some other stud-
ies also reported the use of LSG or LAGB for morbid obesity
or comparisons between the two [14–25] but were excluded
because they did not provide the information we needed for
analysis or their data did not meet our criteria.
Meta-analysis Results
According to our meta-analysis, LSG had a greater effect
than LAGB on EWL at 6 and 12 months. For LAGB, the
mean percentage EWL was 33.9 % after 6 months from six
studies and 37.8 % after 12 months from four studies;
for LSG, EWL was 50.6 % after 6 months and 51.8 %
after 12 months from the same studies. After 6 and
12 months, the mean percentage EWL was higher for
LSG than for LAGB by 33.0 and 27.0 %, respectively,
indicating that, at these time points, LSG had a greater
effect on weight loss than LAGB. LSG was also supe-
rior to LAGB in treating T2DM. According to five
studies, 42 of 68 (61.8 %) T2DM patients experienced
improvement of their diabetes after LAGB, whereas 66
of 80 (82.5 %) T2DM patients improved after LSG, an
increase of 20.7 %. It can be concluded that LSG was a
Fig. 3 Forest plot of comparison: (1) LAGB vs LSG in terms of short-term results, outcome: (1.3) EWL% (12 months). Mean differences are
shown with 95 % CIs
Fig. 4 Funnel plot of
comparison: (1) LAGB vs LSG
in terms of short-term results,
outcome: (1.1) resolution of
diabetes. OR odds ratio
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more effective procedure than LAGB, with a pooled OR
of 0.34 (95 % CI 0.16–0.73; Fig. 1) and pooled mean
differences of −12.55 (95 % CI −15.66 to −9.43; Fig. 2)
and −4.97 (95 % CI −7.58 to −8.36; Fig. 3),
respectively.
Publication Bias
Funnel plots were created to access the publication bias of
the literature. The shapes of the plots did not reveal any
evidence of obvious asymmetry (Figs. 4, 5, and 6).
Discussion
Although LAGB can significantly reduce weight, LSG
had a greater effect on morbid obesity in terms of EWL
and improvement of T2DM. Both LAGB and LSG are
restrictive procedures that achieve EWL by decreasing
the volume of the stomach to reduce food intake to
comparatively low levels. It is widely accepted that the
effects of these procedures are associated with levels of
ghrelin, a 28-amino-acid acylated peptide primarily pro-
duced in endocrine A/X cells located in the fundus of the
stomach [26]. Secretion of ghrelin increases appetite and pro-
motes gastric emptying and intestinal mobility, causing feel-
ings of hunger. Langer et al. [12] reported that ghrelin levels
remained unchanged immediately after LAGB but had in-
creased after 1 and 6 months, whereas ghrelin was decreased
both immediately and at 1 and 6 months after LSG. This is
because the fundus of the stomach, where most ghrelin is
produced, is resected in LSG, though ghrelin levels can be
maintained by up to 45 % after gastrectomy due to secretion
from other sites such as the upper small intestine [26]. Patients
Fig. 5 Funnel plot of
comparison: (1) LAGB vs LSG
in terms of short-term results,
outcome: (1.2) EWL%
(6 months). Mean difference
Fig. 6 Forest plot of
comparison: (1) LAGB vs LSG
in terms of short-term results,
outcome: (1.3) EWL%
(12 months). Mean difference
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who undergo LSG thus have less appetite for food and a
longer-lasting and stronger sensation of fullness, leading to
less food intake and, ultimately, weight loss. However, it is
reported that patients continue to lose weight regardless of
ghrelin levels, which suggest a complex relationship between
this hormone and weight loss that requires further study [11].
Another gastrointestinal hormone, peptide tyrosine–tyro-
sine (PYY), must also be considered. This 36-amino-acid
peptide is produced by endocrine L cells in the distal ileum
and colon and is secreted before lipids reach the distal ileum.
PYY is associated with appetite and has a hunger-reducing
effect. Xanthakos [26] reported that, after intravenous infusion
of PYY in 12 obese and 12 lean human subjects, single meal
intake decreased by 30 % in both obese and lean individuals.
Moreover, PYY reduced levels of ghrelin, enhancing its
hunger-reducing effect. Some reports indicate that, after
LSG, PYY increases following a test meal [27], whereas
PYY does not increase after LAGB; this increases the weight
loss effect of LSG. Overall, both restriction of stomach volume
and hormonal changes contribute to the greater weight loss
achieved by LSG.
Insulin is important in the treatment of diabetes, and it is
believed that insulin resistance is key to the association
between morbid obesity and T2DM. Improved control of
T2DM can be achieved by countering insulin resistance
with increased insulin sensitivity. All surgical interventions
that lead to weight loss will increase insulin sensitivity and
therefore improve T2DM [14]. Improvement of T2DM after
LAGB is directly related to weight loss; that is, the more
weight lost, the more T2DM is improved or even resolved.
However, for LSG, different studies draw differing conclu-
sions. Abbatini [14] reported a statistically significant re-
duction in body mass index 3 months after LSG in a patient
in whom T2DM was not resolved. These data suggest that
improvement of T2DM after LSG may be unrelated to
weight loss. However, Ding concluded that improvement
of T2DM is largely related to weight loss after both LAGB
and LSG and not a consequence of the surgical procedure
used as Hady et al. did [11]. Patients who did not achieve a
good rate of EWL showed little improvement in their dia-
betes [2]. Further studies are needed to clarify these
discrepancies.
Incretins, including glucagon-like peptide 1 (GLP-1),
also play an important role. GLP-1 is secreted by intestinal
endocrine L cells in the ileum and colon and is released into
ingested food, especially that rich in lipids and glucose or
other carbohydrates; it increases pancreatic secretion of
insulin in response to oral glucose ingestion to decrease
the level of glucose in the blood [26]. No increase of
GLP-1 has been reported after LAGB, whereas it is specu-
lated that GLP-1 increases following LSG, which further
helps improve T2DM. The incretin gastric inhibitory pep-
tide is also released as a response to food rich in lipids and
glucose. These hormones not only improve T2DM but also
help reduce weight.
All of the above factors may account for the weight loss
observed after LSG and LABG and explain why LSG has a
greater effect on EWL and improvement of T2DM. How-
ever, LAGB has advantages over LSG including easier
technique, shorter operative time, and fewer early compli-
cations [28]. Furthermore, LAGB is less invasive than LSG
and is totally reversible. These factors contribute to the
popularity of LAGB among obese patients, but in terms of
effect we consider LSG a better option.
There are limitations to this meta-analysis to which we
must pay attention. First, the sample size of some of the
studies was quite low, as was the number of studies included
in our meta-analysis; this may have biased the results.
Second, not all of the included trials were randomized
because of a lack of qualified randomized studies providing
the required details. Third, we did not compare improve-
ments in other comorbidities following LAGB and LSG,
and these factors may be important in assessing and
recommending a procedure. Because LSG is a comparatively
new procedure that has become popular in recent years,
there is also concern about the long-term results; the
follow-up periods in most reports are 6 or 12 months, and
the studies analyzed here provided relatively short-term
findings. Some studies that reported 3-year results were
not included in this meta-analysis because of insufficient
data, but their numbers are low. There are few reports with a
follow-up period of 5 years or more. However, we believe
that, with greater awareness and the increasing popularity of
bariatric surgery, more long-term follow-up reports will be
published.
In summary, this meta-analysis showed LSG to be a more
effective procedure for morbid obesity than LABG, with a
greater effect on EWL and improvement of T2DM. Larger,
randomized, and long-term follow-up studies need to be
conducted to compare the efficacy of LSG, LAGB, and lapa-
roscopic Roux-en-Y gastric bypass.
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